home / stock / pstv / pstv news

PSTV News and Press, PLUS THERAPEUTICS Inc. From 09/13/23

Stock Information
Company Name: PLUS THERAPEUTICS Inc.
Stock Symbol: PSTV
Market: NYSE
Website: plustherapeutics.com
Menu
PSTV PSTV Quote PSTV Short PSTV News PSTV Articles PSTV Message Board
Get PSTV Alerts

News, Short Squeeze, Breakout and More Instantly...
PSTV - Avalo Therapeutics, Rocket Pharmaceuticals, Acelyrin among healthcare movers

2023-09-13 10:00:09 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
PSTV - GRAB, BIOC and PSTV among pre-market losers

2023-09-13 08:18:57 ET Losers: Nature Wood Group Limited ( NWGL ) -15% on prices $6.75M equity offering . Evolution Petroleum Corporation ( EPM ) -13% . after Q4 earning release . Applied Optoelectronics ( AAOI ) -13% amends equity pact with R...

PSTV - Plus Therapeutics gets $1.9M advance payment from CPRIT

2023-09-11 12:44:57 ET More on Plus Therapeutics Seeking Alpha’s Quant Rating on Plus Therapeutics Historical earnings data for Plus Therapeutics Financial information for Plus Therapeutics Plus Therapeutics Q2 2023 Earnings Call Transcript Bio...

PSTV - Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today anno...
PSTV - Biocept gains on licensing pact with Plus Therapeutics for cancer test

2023-09-08 08:38:43 ET More on Biocept, Plus, etc. Biocept, Inc. ( BIOC ) Business Update Conference Call (Transcript) Plus Therapeutics, Inc. ( PSTV ) Q2 2023 Earnings Call Transcript For further details see: Biocept gains on licensing pact with Plus The...

PSTV - Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay

CNSide™ assay is the gold standard diagnostic cerebrospinal fluid (CSF) assay for patients with suspected central nervous system (CNS) cancers As part of the agreement, Plus obtains a nonexclusive license and option for exclusivity for patients receiving CNS radiotherapy ...

PSTV - Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase

AUSTIN, Texas, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today anno...
PSTV - Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., Preside...

PSTV - Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript

2023-08-14 21:52:02 ET Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Conference Call August 14, 2023 17:00 ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Chief Financial Officer Conference Call Participants ...

PSTV - Plus Therapeutics GAAP EPS of -$0.59 beats by $1.44

2023-08-14 16:07:41 ET More on Plus Therapeutics Plus stock rises as radiotherapy shows promise in ongoing brain cancer studies Plus Therapeutics Q3 net loss widens Y/Y Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating Plus Therapeutics fina...
Previous 10 Next 10